M. Ducreux says that the main focus of genomic research in upper GI cancers is in gastric carcinoma. He emphasizes that understanding of carcinogenesis is key in achieving progress in the treatment and discusses molecular subtypes of gastric cancer. He predicts that in a near future oncologists will be able to select patients and to propose immunotherapy probably in a sub-population of patients with MSI type gastric carcinoma.